135 related articles for article (PubMed ID: 31822364)
21. Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition.
Huang D; Duan H; Huang H; Tong X; Han Y; Ru G; Qu L; Shou C; Zhao Z
Sci Rep; 2016 Feb; 6():20502. PubMed ID: 26846307
[TBL] [Abstract][Full Text] [Related]
22. Disruption of FOXO3a-miRNA feedback inhibition of IGF2/IGF-1R/IRS1 signaling confers Herceptin resistance in HER2-positive breast cancer.
Luo L; Zhang Z; Qiu N; Ling L; Jia X; Song Y; Li H; Li J; Lyu H; Liu H; He Z; Liu B; Zheng G
Nat Commun; 2021 May; 12(1):2699. PubMed ID: 33976188
[TBL] [Abstract][Full Text] [Related]
23. MMP7 Induces T-DM1 Resistance and Leads to the Poor Prognosis of Gastric Adenocarcinoma
Li H; Xu X; Liu Y; Li S; Zhang D; Meng X; Lu L; Li Y
Anticancer Agents Med Chem; 2018; 18(14):2010-2016. PubMed ID: 30501604
[TBL] [Abstract][Full Text] [Related]
24. Quantitative proteomics profiling reveals activation of mTOR pathway in trastuzumab resistance.
Liu W; Chang J; Liu M; Yuan J; Zhang J; Qin J; Xia X; Wang Y
Oncotarget; 2017 Jul; 8(28):45793-45806. PubMed ID: 28507275
[TBL] [Abstract][Full Text] [Related]
25. Establishment of a Patient-derived Xenograft for Development of Personalized HER2-targeting Therapy in Gastric Cancer.
Shin SH; Park SS; Ju EJ; Park J; Ko EJ; Hwang JJ; Suh YA; Jang SJ; Lee JS; Ko BK; Kim KT; Lee JS; Song SY; Jeong SY; Choi EK
Anticancer Res; 2018 Jan; 38(1):287-293. PubMed ID: 29277785
[TBL] [Abstract][Full Text] [Related]
26. HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer.
Sampera A; Sánchez-Martín FJ; Arpí O; Visa L; Iglesias M; Menéndez S; Gaye É; Dalmases A; Clavé S; Gelabert-Baldrich M; Poulsen TT; Kragh M; Bellosillo B; Albanell J; Rovira A; Montagut C
Mol Cancer Ther; 2019 Nov; 18(11):2135-2145. PubMed ID: 31484705
[TBL] [Abstract][Full Text] [Related]
27. Kinetic Modeling of DUSP Regulation in Herceptin-Resistant HER2-Positive Breast Cancer.
Buiga P; Elson A; Tabernero L; Schwartz JM
Genes (Basel); 2019 Jul; 10(8):. PubMed ID: 31357550
[TBL] [Abstract][Full Text] [Related]
28. ARPP-19 Mediates Herceptin Resistance via Regulation of CD44 in Gastric Cancer.
Gao X; Lu C; Chen C; Sun K; Liang Q; Shuai J; Wang X; Xu Y
Onco Targets Ther; 2020; 13():6629-6643. PubMed ID: 32753897
[TBL] [Abstract][Full Text] [Related]
29. WEE1 inhibition reverses trastuzumab resistance in HER2-positive cancers.
Jin MH; Nam AR; Bang JH; Oh KS; Seo HR; Kim JM; Yoon J; Kim TY; Oh DY
Gastric Cancer; 2021 Sep; 24(5):1003-1020. PubMed ID: 33723720
[TBL] [Abstract][Full Text] [Related]
30. HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells.
Park KS; Hong YS; Choi J; Yoon S; Kang J; Kim D; Lee KP; Im HS; Lee CH; Seo S; Kim SW; Lee DH; Park SR
BMB Rep; 2018 Dec; 51(12):660-665. PubMed ID: 30591093
[TBL] [Abstract][Full Text] [Related]
31. Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.
Díaz-Serrano A; Angulo B; Dominguez C; Pazo-Cid R; Salud A; Jiménez-Fonseca P; Leon A; Galan MC; Alsina M; Rivera F; Plaza JC; Paz-Ares L; Lopez-Rios F; Gómez-Martín C
Oncologist; 2018 Sep; 23(9):1092-1102. PubMed ID: 29700210
[TBL] [Abstract][Full Text] [Related]
32. DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance.
Takegawa N; Nonagase Y; Yonesaka K; Sakai K; Maenishi O; Ogitani Y; Tamura T; Nishio K; Nakagawa K; Tsurutani J
Int J Cancer; 2017 Oct; 141(8):1682-1689. PubMed ID: 28677116
[TBL] [Abstract][Full Text] [Related]
33. Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer.
Hori A; Shimoda M; Naoi Y; Kagara N; Tanei T; Miyake T; Shimazu K; Kim SJ; Noguchi S
Breast Cancer Res; 2019 Aug; 21(1):88. PubMed ID: 31387614
[TBL] [Abstract][Full Text] [Related]
34. Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer.
Hergueta-Redondo M; Sarrio D; Molina-Crespo Á; Vicario R; Bernadó-Morales C; Martínez L; Rojo-Sebastián A; Serra-Musach J; Mota A; Martínez-Ramírez Á; Castilla MÁ; González-Martin A; Pernas S; Cano A; Cortes J; Nuciforo PG; Peg V; Palacios J; Pujana MÁ; Arribas J; Moreno-Bueno G
Oncotarget; 2016 Aug; 7(35):56295-56308. PubMed ID: 27462779
[TBL] [Abstract][Full Text] [Related]
35. Cancer-adipose tissue interaction and fluid flow synergistically modulate cell kinetics, HER2 expression, and trastuzumab efficacy in gastric cancer.
Akutagawa T; Aoki S; Yamamoto-Rikitake M; Iwakiri R; Fujimoto K; Toda S
Gastric Cancer; 2018 Nov; 21(6):946-955. PubMed ID: 29696406
[TBL] [Abstract][Full Text] [Related]
36. Statins enhance the efficacy of HER2-targeting radioligand therapy in drug-resistant gastric cancers.
Rao Y; Samuels Z; Carter LM; Monette S; Panikar SS; Pereira PMR; Lewis JS
Proc Natl Acad Sci U S A; 2023 Apr; 120(14):e2220413120. PubMed ID: 36972439
[TBL] [Abstract][Full Text] [Related]
37. Evolutionary Expression of HER2 Conferred by Chromosome Aneuploidy on Circulating Gastric Cancer Cells Contributes to Developing Targeted and Chemotherapeutic Resistance.
Li Y; Zhang X; Liu D; Gong J; Wang DD; Li S; Peng Z; Li Y; Wang X; Lin PP; Li M; Shen L
Clin Cancer Res; 2018 Nov; 24(21):5261-5271. PubMed ID: 30012565
[No Abstract] [Full Text] [Related]
38. Trastuzumab Inhibits Growth of HER2-Negative Gastric Cancer Cells Through Gastrin-Initialized CCKBR Signaling.
Cui Y; Li SB; Peng XC; Wu J; Fu GH
Dig Dis Sci; 2015 Dec; 60(12):3631-41. PubMed ID: 26173505
[TBL] [Abstract][Full Text] [Related]
39. A new mechanism of trastuzumab resistance in gastric cancer: MACC1 promotes the Warburg effect via activation of the PI3K/AKT signaling pathway.
Liu J; Pan C; Guo L; Wu M; Guo J; Peng S; Wu Q; Zuo Q
J Hematol Oncol; 2016 Aug; 9(1):76. PubMed ID: 27581375
[TBL] [Abstract][Full Text] [Related]
40. Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer.
Kim HP; Han SW; Song SH; Jeong EG; Lee MY; Hwang D; Im SA; Bang YJ; Kim TY
Oncogene; 2014 Jun; 33(25):3334-41. PubMed ID: 23873022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
